A5011499566- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Head and Neck Cancer Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Thyroid Cancer Diagnosis and Treatment
- Autophagy in Disease and Therapy
- Statistical Methods in Clinical Trials
- Ubiquitin and proteasome pathways
- Effects of Radiation Exposure
- Burn Injury Management and Outcomes
- Climate Change and Health Impacts
- Radiomics and Machine Learning in Medical Imaging
- Social Media in Health Education
- DNA Repair Mechanisms
Swedish Medical Center
2023-2024
Seattle University
2023
University of Washington
2023
University of Hawaii System
2023
Harborview Medical Center
2023
University of Hawaiʻi at Mānoa
2023
University of California, Los Angeles
2016-2019
UCLA Medical Center
2017
Abstract We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated anti-PD-1 antibody, pembrolizumab. The discovery cohort was drawn from phase I Keynote 001 trial, whereas validation 002, 006, EAP trials non–small cell (NSCLC) 001. Liver metastasis associated reduced shortened progression-free survival [PFS; objective rate (ORR), 30.6%; median PFS, 5.1 months] compared without (ORR, 56.3%; 20.1 months) P ≤...
We retrospectively analyzed non-small cell lung cancer (NSCLC) patients from a single center treated with pembrolizumab on the KEYNOTE-001 trial and evaluated association between treatment-related adverse events (trAEs) clinical outcomes. Investigators reported AEs graded them according to Common Terminology Criteria for Adverse Events v4.0, labeling as unlikely, possibly, or probably treatment-related. labeled possibly/probably related were considered trAEs this analysis. The relationship...
Significance Pancreatic cancer is notoriously treatment resistant. These tumors rely on lysosome-dependent recycling pathways to generate substrates for metabolism, which are inhibited by chloroquine (CQ) and its derivatives. However, clinical efficacy of CQ as a monotherapy or combined with standard-of-care regimens has been limited. Using an unbiased kinome screen, we identify replication stress induced vulnerability due impaired de novo nucleotide biosynthesis find that combination...
Abstract BACKGROUND: Metastatic non-small cell lung cancer (NSCLC) tumors have adopted methods to evade immune detection and/or clearance. This can occur via overexpression of programmed death ligand 1 (PD-L1). Response rate, progression free survival and overall with PD-1 inhibitors are greater in high tumor PD-L1 expression (Garon et al, NEJM 2015, Paz-Ares ASCO 2015). There has been interest using as a treatment selection criterion. Currently available screening involve invasive biopsy...
Background: Traditionally, study results have been presented as abstracts at major scientific meetings the conclusion of analysis. Recently, presentations studies in progress and updates to previously data allowed meetings. The frequency implications a single being multiple times, particularly high profile oral presentations, not fully evaluated. Methods: To identify from an approximately 1-year period international conferences for three societies devoted largely or part lung cancer research...
e20662 Background: The 6 FDA drug approvals for non-small cell lung cancer (NSCLC) in 2015 included 2 programmed death protein 1 (PD-1) inhibitors and a 3rd generation (gen) epidermal growth factor receptor (EGFR) inhibitor. For previously treated NSCLC, nivolumab (nivo) was approved squamous (Mar 4) non-squamous (Oct 2) disease (dz), pembrolizumab (pembro) PD-L1+ dz according to companion diagnostic 9). Osimertinib EGFR T790M+ mutant (Nov 13). National Comprehensive Cancer Network (NCCN)...
<p>Supplementary Table S6a: Objective response rate (ORR) in the 95 NSCLC patients from UCLA cohort that had at least 1 set of thyroid values obtained on trial available for analysis stratified by presence or absence an abnormal TSH value varying qualities (Any, High, Low, Both High and Low noted).</p>
<p>Table S3: The occurrence of a treatment related AE (trAE) in the 97 patients treated at UCLA on KEYNOTE-001 clinical trial, stratified by history thoracic radiation therapy (TRT) or prior to any location. P values computed via Fisher's exact test.</p>
<p>Table S1: All adverse events occurring in > 5% of patients the UCLA NSCLC cohort 97 treated on KEYNOTE-001.</p>
<p>Supplementary Table S5a: Cox proportional hazards models for progression-free survival (PFS) with number of treatment related select adverse events included as a time-varying covariate. Listed are results from both unadjusted and adjusted models. Hazard ratio estimates marked '(+1)' correspond to the incremental effect unit increase in relevant predictor.</p>
<p>Supplementary Figure S1A-B. ORR, PFS, and OS analysis for UCLA NSCLC cohort of KEYNOTE-001 trial. all 97 patients in the trial stratified by occurrence a (A) treatment related adverse event (trAE) or (B) select AE.</p>
<p>Table S2: Demographics of the 97 NSCLC patients treated at UCLA on KEYNOTE-001 (N=97) compared with demographics total study population (n=495). Of note, cohort is included in 495 patients.</p>
<p>Supplementary Table 4a: Objective response rate (ORR), progression-free survival (PFS), and overall stratified by the incidence of a grade 2 or higher treatment related AE (trAE) trAE varying degrees attribution (possible probable). Included are all 97 NSCLC patients treated at UCLA on KEYNOTE-001 with available follow-up data.</p>
<div>Abstract<p>We retrospectively analyzed non–small cell lung cancer (NSCLC) patients from a single center treated with pembrolizumab on the KEYNOTE-001 trial and evaluated association between treatment-related adverse events (trAEs) clinical outcomes. Investigators reported AEs graded them according to Common Terminology Criteria for Adverse Events v4.0, labeling as unlikely, possibly, or probably treatment-related. labeled possibly/probably related were considered trAEs this...
<p>Table S1: All adverse events occurring in > 5% of patients the UCLA NSCLC cohort 97 treated on KEYNOTE-001.</p>
<p>Table S2: Demographics of the 97 NSCLC patients treated at UCLA on KEYNOTE-001 (N=97) compared with demographics total study population (n=495). Of note, cohort is included in 495 patients.</p>
<p>Supplementary Figure S1A-B. ORR, PFS, and OS analysis for UCLA NSCLC cohort of KEYNOTE-001 trial. all 97 patients in the trial stratified by occurrence a (A) treatment related adverse event (trAE) or (B) select AE.</p>
<p>Supplementary Table S5a: Cox proportional hazards models for progression-free survival (PFS) with number of treatment related select adverse events included as a time-varying covariate. Listed are results from both unadjusted and adjusted models. Hazard ratio estimates marked '(+1)' correspond to the incremental effect unit increase in relevant predictor.</p>
<p>Supplementary Table S6a: Objective response rate (ORR) in the 95 NSCLC patients from UCLA cohort that had at least 1 set of thyroid values obtained on trial available for analysis stratified by presence or absence an abnormal TSH value varying qualities (Any, High, Low, Both High and Low noted).</p>
<p>Supplementary Table 4a: Objective response rate (ORR), progression-free survival (PFS), and overall stratified by the incidence of a grade 2 or higher treatment related AE (trAE) trAE varying degrees attribution (possible probable). Included are all 97 NSCLC patients treated at UCLA on KEYNOTE-001 with available follow-up data.</p>
<p>Table S3: The occurrence of a treatment related AE (trAE) in the 97 patients treated at UCLA on KEYNOTE-001 clinical trial, stratified by history thoracic radiation therapy (TRT) or prior to any location. P values computed via Fisher's exact test.</p>